InvestorsHub Logo
Followers 2
Posts 160
Boards Moderated 0
Alias Born 03/14/2012

Re: None

Friday, 04/20/2012 1:35:39 PM

Friday, April 20, 2012 1:35:39 PM

Post# of 3141
I like the sound of this.

Summary

We are dedicated to developing safe and effective therapies for significant life-threatening diseases including organ failure and cancer. We are attacking these fatal disorders by targeting galectin-3, a member of the galectin family of proteins that is implicated in their pathology. Our lead product candidate against galectin-3, GCS-100, has been tested in more than 100 patients and is generally well tolerated. We have an experienced management team dedicated to accomplishing our corporate milestones, as well as sufficient cash to execute on these near-term activities. Please visit us at http://www.ljpc.com.

"I love it when a plan comes together!"